Evaluation of the efficacy of oral deferiprone in β‐thalassemia major by multislice multiecho T2*
- 5 January 2006
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 76 (3) , 183-192
- https://doi.org/10.1111/j.1600-0609.2005.00587.x
Abstract
Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients. T2* magnetic resonance imaging (MRI) with a single measurement in the mid-ventricular septum was validated as a quantitative evaluation of myocardial iron overload. Previous studies suggested a marked heterogeneity of iron distribution in the myocardium. We set up a multislice multiecho T2* MRI for the detection of this heterogeneity. The aim of our study was to investigate differences between the L1 vs. the subcutaneous desferrioxamine (DF)-treated patients using this new approach. Thirty-six beta-TM patients (age 29 +/- 8 yr) underwent MRI. Eighteen patients received long-term L1, and 18 other patients matched for age and sex received DF. T2* multiecho sequences on three short axis views of the left ventricle were obtained and analyzed by custom-made software. In each slice, the myocardium was automatically segmented into four segments. Cine-dynamic images were also obtained to evaluate biventricular function. For multislice T2* technique, the coefficient of variation for intra- and inter-observer, and inter-study reproducibility was 3.9%, 4.7%, and 5.5%, respectively. The global heart T2* value was significantly higher in the L1 vs. DF group (35 +/- 7 vs. 27 +/- 2 ms; P = 0.02). The number of segments with normal T2* value (>20 ms) was significantly higher in the L1 vs. the DF group (11 +/- 1 vs. 8 +/- 5 segments; P = 0.03). We did not detect significant differences in biventricular function parameters. This new approach confirms that L1 could be more effective than DF in removal of myocardial iron.Keywords
This publication has 37 references indexed in Scilit:
- Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBritish Journal of Haematology, 2004
- Myocardial iron loading in transfusion-dependent thalassemia and sickle cell diseaseBlood, 2004
- Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemiaJournal of Magnetic Resonance Imaging, 2003
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patientsThe Lancet, 1990
- Deferoxamine-induced growth retardation in patients with thalassemia majorThe Journal of Pediatrics, 1988
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985
- Iron in the heartThe American Journal of Medicine, 1971
- CARDIAC INVOLVEMENT IN HEMOCHROMATOSISThe Lancet Healthy Longevity, 1954